A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 120
- Registration Number
- NCT01843790
- Locations
- 🇺🇸
Denver Nephrology, Denver, Colorado, United States
🇺🇸Southwest Clinical Research Institute, LLC, Tempe, Arizona, United States
🇺🇸California Institute of Renal Research, La Mesa, California, United States
Safety Study of GCS-100 to Treat Chronic Kidney Disease
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 29
- Registration Number
- NCT01717248
- Locations
- 🇺🇸
Denver Nephrologists, PC, Denver, Colorado, United States
🇺🇸Renal Associates PA / Research Division, San Antonio, Texas, United States
🇺🇸California Institue of Renal Research, La Mesa, California, United States
GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Registration Number
- NCT00776802
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 9
- Registration Number
- NCT00609817
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Froedtert & Medical College Clinics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸University of Florida, Gainesville, Florida, United States
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 12
- Registration Number
- NCT00514696
- Locations
- 🇺🇸
Dayton Oncology & Hematology, Kettering, Ohio, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸Tyler Cancer Center, Tyler, Texas, United States
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Registration Number
- NCT00390091
- Locations
- 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Study of LJP 394 in Lupus Patients With History of Renal Disease
- First Posted Date
- 2004-08-17
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 943
- Registration Number
- NCT00089804
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Miami Children's Hospital, Miami, Florida, United States
🇺🇸CRIA Research, Fort Lauderdale, Florida, United States
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-09-25
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 330
- Registration Number
- NCT00035308
- Locations
- 🇺🇸
Emory University School of Medicine, Renal Division, Atlanta, Georgia, United States
🇺🇸Rheumatology Associates, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States